Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty

Summary

The purpose of this study is to determine the effect of Losartan, an Angiotensin II Receptor Blocker (ARB), on the formation development of arthrofibrosis in patients who have had a primary total knee arthroplasty. This study aims to assess the post-operative range of motion and the incidence of MUA within three months following the index arthroplasty in the treatment arm (losartan) and the control arm.

Timeline

Start

2024-07-01

Primary completion

2026-01-01

Completion

2026-01-01

Outcome

Outcome not reported

Stopped: “Study team unable to identify method for approval of the medication as standard of care and compounded.”

Drugs

Indications